204 related articles for article (PubMed ID: 38147151)
1. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
2. Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein.
Horii Y; Iniwa T; Onitsuka M; Tsukimoto J; Tanaka Y; Ike H; Fukushi Y; Ando H; Takeuchi Y; Nishioka SI; Tsuji D; Ikuo M; Yamazaki N; Takiguchi Y; Ishimaru N; Itoh K
Mol Ther Methods Clin Dev; 2022 Jun; 25():297-310. PubMed ID: 35573044
[TBL] [Abstract][Full Text] [Related]
3. Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Seyrantepe V; Landry K; Trudel S; Hassan JA; Morales CR; Pshezhetsky AV
J Biol Chem; 2004 Aug; 279(35):37021-9. PubMed ID: 15213228
[TBL] [Abstract][Full Text] [Related]
4. In Cellulo Crystallization of Human Neuraminidase 1 and Biological Roles of
Tsukimoto J; Takeuchi Y; Horii Y; Iniwa T; Fukushi Y; Nishioka SI; Itoh K
ACS Appl Bio Mater; 2022 Jan; 5(1):205-213. PubMed ID: 35014832
[TBL] [Abstract][Full Text] [Related]
5. Structure of the immunoregulatory sialidase NEU1.
Gorelik A; Illes K; Mazhab-Jafari MT; Nagar B
Sci Adv; 2023 May; 9(20):eadf8169. PubMed ID: 37205763
[TBL] [Abstract][Full Text] [Related]
6. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
7. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
8. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Kwak JE; Son MY; Son YS; Son MJ; Cho YS
Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
[TBL] [Abstract][Full Text] [Related]
10. [Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].
Itoh K; Nishioka SI; Hidaka T; Tsuji D; Maita N
Yakugaku Zasshi; 2018; 138(7):885-893. PubMed ID: 29962464
[TBL] [Abstract][Full Text] [Related]
11. Structure of the murine lysosomal multienzyme complex core.
Gorelik A; Illes K; Hasan SMN; Nagar B; Mazhab-Jafari MT
Sci Adv; 2021 May; 7(20):. PubMed ID: 33980489
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
13. Galactosialidosis: review and analysis of CTSA gene mutations.
Caciotti A; Catarzi S; Tonin R; Lugli L; Perez CR; Michelakakis H; Mavridou I; Donati MA; Guerrini R; d'Azzo A; Morrone A
Orphanet J Rare Dis; 2013 Aug; 8():114. PubMed ID: 23915561
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal localization of Japanese medaka (Oryzias latipes) Neu1 sialidase and its highly conserved enzymatic profiles with human.
Ryuzono S; Takase R; Oishi K; Ikeda A; Chigwechokha PK; Funahashi A; Komatsu M; Miyagi T; Shiozaki K
Gene; 2016 Jan; 575(2 Pt 2):513-523. PubMed ID: 26432003
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of NEU1 gene in sialidosis.
Seyrantepe V; Poupetova H; Froissart R; Zabot MT; Maire I; Pshezhetsky AV
Hum Mutat; 2003 Nov; 22(5):343-52. PubMed ID: 14517945
[TBL] [Abstract][Full Text] [Related]
16. Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex.
Lukong KE; Landry K; Elsliger MA; Chang Y; Lefrancois S; Morales CR; Pshezhetsky AV
J Biol Chem; 2001 May; 276(20):17286-90. PubMed ID: 11279074
[TBL] [Abstract][Full Text] [Related]
17. Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient.
Penzel R; Uhl J; Kopitz J; Beck M; Otto HF; Cantz M
FEBS Lett; 2001 Jul; 501(2-3):135-8. PubMed ID: 11470272
[TBL] [Abstract][Full Text] [Related]
18. In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization.
Bonardi D; Ravasio V; Borsani G; d'Azzo A; Bresciani R; Monti E; Giacopuzzi E
PLoS One; 2014; 9(8):e104229. PubMed ID: 25153125
[TBL] [Abstract][Full Text] [Related]
19. Novel Nile tilapia Neu1 sialidases: Molecular cloning and biochemical characterization of the sialidases Neu1a and Neu1b.
Honda A; Chigwechokha PK; Takase R; Hayasaka O; Fujimura K; Kotani T; Komatsu M; Shiozaki K
Gene; 2020 Jun; 742():144538. PubMed ID: 32184168
[TBL] [Abstract][Full Text] [Related]
20. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Seol B; Kim YD; Cho YS
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
